Cargando…
Combination Therapy Using Chelating Agent and Zinc for Wilson’s Disease
There is no clear international consensus regarding the optimal medication therapy for treating Wilson’s disease (WD). This study systematically reviews the effectiveness of various medication therapies in common use, specifically focusing on preliminary findings concerning the combination of a chel...
Autores principales: | Chen, Jui-Chi, Chuang, Cheng-Hung, Wang, Jing-Doo, Wang, Chi-Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666238/ https://www.ncbi.nlm.nih.gov/pubmed/26692828 http://dx.doi.org/10.1007/s40846-015-0087-7 |
Ejemplares similares
-
Symptom aggravation after withdrawal of metal chelating agent therapy in patients with Wilson's disease
por: Zhou, Xiangxue, et al.
Publicado: (2023) -
The Effect of Chelation Therapy on the Amino Aciduria and Peptiduria of Wilson's Disease
por: Asatoor, A. M., et al.
Publicado: (1983) -
Hypopituitarism in Wilson’s disease resolved after copper-chelating therapy
por: Dauth, Nina, et al.
Publicado: (2021) -
Hyaluronate/black phosphorus complexes as a copper chelating agent for Wilson disease treatment
por: Kim, Seong-Jong, et al.
Publicado: (2021) -
Combined sodium Dimercaptopropanesulfonate and zinc versus D-penicillamine as first-line therapy for neurological Wilson’s disease
por: Zhang, Jing, et al.
Publicado: (2020)